One To Watch

Saol Therapeutics

Company Overview

A privately held, clinical-stage pharmaceutical company pursuing the first FDA-approved treatment for pyruvate dehydrogenase complex deficiency, a fatal pediatric mitochondrial disease with no approved options. Saol Therapeutics (pronounced "Sail") develops late-stage programs across orphan diseases and CNS conditions including pain and spasticity. Its two active clinical programs are SL1009 for PDCD and SL1002 for osteoarthritis-related knee pain.

Headquarters and Global Presence

Saol is headquartered in Roswell, Georgia, with additional operations in Dublin, Ireland and Hamilton, Bermuda. The tri-jurisdiction footprint reflects a structure common among privately held specialty pharma companies operating across US and international regulatory environments.

Founding and History

Saol describes itself as guided by a team of seasoned entrepreneurs with track records across large and small, public and private pharmaceutical companies. The company has reached late-stage development without conducting an IPO, remaining privately held through its current NDA review cycle.

Therapy Areas and Focus

PDCD is a mitochondrial disorder of carbohydrate oxidation affecting primarily the brain, characterized by ATP production failure, lactic acidosis, developmental delay, and early childhood death. Approximately 90 children are diagnosed annually in the US, and fewer than 1,000 Americans are affected in total. The ketogenic diet is currently the only management option; no FDA-approved therapy exists. SL1002 addresses the separate, much larger population of osteoarthritis patients, estimated at 27 million Americans with knee pain.

Technology Platforms and Modalities

SL1009 is sodium dichloroacetate (DCA), an oral solution that targets the pyruvate dehydrogenase complex to restore impaired carbohydrate oxidation in mitochondria. A defining feature is its pairing with a proprietary dose-determining genetic test, making individualized dosing based on the patient's specific gene variant central to the treatment approach. SL1002 is a proprietary chemoneurolytic agent delivered by injection, designed to provide durable pain relief in osteoarthritis through targeted nerve disruption. Both programs are described as well-characterized molecules with optimized, patent-protected formulations.

Key Pipeline and Programs

SL1009 (sodium dichloroacetate, oral solution) is Saol's lead asset, currently under FDA review in its second NDA cycle for PDCD (NCT02616484). The pivotal Phase III study enrolled 34 children aged 6 months through 17 years in a randomized, double-blind, placebo-controlled design, with a caregiver-reported Observer Reported Outcome survey as the primary efficacy measure. The NDA carries Priority Review, Orphan Drug Designation, and Rare Pediatric Disease Designation; the PDUFA date is December 30, 2026. SL1002 is a proprietary chemoneurolytic injection evaluated in a multi-center, randomized, double-blind, placebo-controlled Phase II dose-escalation study (NCT05470608) enrolling 132 patients with knee pain from osteoarthritis across four cohorts, with a 26-week follow-up period. Phase II enrollment is complete across both pain and spasticity indications, and the program is positioned as a potential multi-indication franchise given its mechanism. Principal investigators are Peter W. Stacpoole, MD, PhD at the University of Florida for SL1009, and Zachary L. McCormick, MD at the University of Utah for SL1002.

Recent Developments

On July 28, 2026, the FDA accepted Saol's resubmitted NDA for SL1009 as a Class 2 submission, setting a PDUFA action date of December 30, 2026. The resubmission, filed June 30, 2026, followed a Complete Response Letter issued August 27, 2025, which raised no safety or manufacturing concerns, and two subsequent FDA meetings in December 2025 and March 2026 that guided Saol to provide additional survival analyses from existing data rather than conduct new trials. Separately, Saol and Medosome Biotec filed a Humanitarian Device Exemption application for the companion genetic test required alongside SL1009, a regulatory step that must clear in parallel with the NDA for the full treatment package to reach patients.

Key Personnel

Dave Penake serves as Chief Executive Officer, and has been the public face of Saol's NDA interactions with the FDA across both review cycles. Brian Nappi serves as Senior Vice President, Strategy.

Strategic Partnerships

Saol has collaborated with Medosome Biotec on the dose-determining genetic test companion diagnostic for SL1009, with the two companies jointly filing the Humanitarian Device Exemption application. The SL1009 Phase III program has received grant support from the NIH and FDA, reflecting the program's designation as a public health priority in a disease area with no approved alternatives.

FAQ Section

PDCD affects roughly 90 newborns annually in the US, but the absence of any FDA-approved therapy means families currently rely on dietary management alone in a condition with high early mortality. A successful approval would also generate a Priority Review Voucher under the Rare Pediatric Disease statute, which carries significant transferable commercial value and represents a meaningful financial asset for a privately held company of Saol's size.

PDCD is caused by mutations in genes encoding components of the pyruvate dehydrogenase complex, most commonly PDHA1 in an X-linked pattern, impairing the conversion of pyruvate to acetyl-CoA and starving cells of ATP. DCA activates the complex by inhibiting its inactivating kinase, restoring partial carbohydrate oxidation and reducing the toxic accumulation of lactate. The genetically heterogeneous nature of the disease is why Saol's individualized dosing approach, tied to each patient's specific variant, is central to the program's design.

DCA has been studied in metabolic and mitochondrial diseases for decades, but Saol's contribution is a proprietary oral formulation paired with a required companion genetic test that calibrates dosing to individual genotype, addressing the variable pharmacogenomics that complicated earlier, undifferentiated DCA use. The companion test is being reviewed separately under a Humanitarian Device Exemption filed with Medosome Biotec, meaning regulatory clearance of both elements is needed before patients can receive the full labeled treatment.

The FDA issued a Complete Response Letter in August 2025 citing specific analytical observations but no safety or manufacturing deficiencies, a meaningful distinction that left the core data package intact. Following Type A and Type C meetings, the FDA accepted additional survival analyses from existing trial data as sufficient to support resubmission, avoiding the need for new clinical work. The resubmission was accepted as a Class 2 filing with a PDUFA date of December 30, 2026, giving SL1009 a defined six-month review clock.

SL1002 targets a vastly larger market than SL1009, addressing knee pain in osteoarthritis, a condition affecting an estimated 27 million Americans. As a chemoneurolytic injection with a proprietary, patent-protected formulation, it has completed Phase II enrollment across pain and spasticity indications, making it a potential multi-indication asset if Phase II data support advancement. The two-program structure gives Saol both a near-term regulatory catalyst in an ultra-rare disease and a longer-horizon commercial opportunity in a high-volume indication.

SL1009 is the more advanced asset, having completed Phase III enrollment and now in active FDA review with a December 2026 PDUFA date. SL1002 has completed Phase II enrollment in both its pain and spasticity indications, with results pending. Saol is therefore a company on the cusp of its first potential approval, while simultaneously carrying a Phase II asset that will require Phase III investment to advance.

Key watchpoints include:

The FDA's action on the SL1009 NDA by December 30, 2026, which will determine whether Saol becomes the first company to offer an approved therapy for PDCD.
The separate HDE review for the companion genetic test filed with Medosome Biotec, without which the full SL1009 treatment package cannot be commercially deployed.
Phase II data readout from SL1002 in osteoarthritis knee pain, which will define whether Saol has a viable second commercial program.
The potential issuance of a Priority Review Voucher upon SL1009 approval, a financially material event for a privately held company.
Any FDA request for additional information during the current review cycle, given the history of the Complete Response Letter, which could delay or complicate the December 2026 decision date.

Want to Update your Company's Profile?